CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Tahir Misbah Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2026-03-02 | Tahir Misbah Chief Financial Officer | Grant or award · Restricted Stock Units | +20,000 | 20,000 | ||
| 2026-03-02 | Courtney Phillips GC and Corp. Secretary | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2026-03-02 | Courtney Phillips GC and Corp. Secretary | Grant or award · Restricted Stock Units | +16,000 | 16,000 | ||
| 2026-03-02 | Coloma Jason V Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2026-03-02 | Coloma Jason V Chief Executive Officer | Grant or award · Restricted Stock Units | +75,000 | 75,000 | ||
| 2026-02-27 | Dandekar Atul CSBO | Option exercise 10b5-1 | +7,500 | $10.42 | $78K | 18,003 |
| 2026-02-27 | Dandekar Atul CSBO | Sale 10b5-1 | −3,739 | $45.13 | $169K | 14,264 |
| 2026-02-27 | Dandekar Atul CSBO | Sale 10b5-1 | −3,761 | $45.72 | $172K | 10,503 |
| 2026-02-27 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 59,143 | ||
| 2026-02-02 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +4,844 | $10.42 | $50K | 17,809 |
| 2026-02-02 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +156 | $10.42 | $2K | 17,965 |
| 2026-02-02 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −200 | $44.15 | $9K | 17,765 |
| 2026-02-02 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −4,064 | $46.03 | $187K | 13,701 |
| 2026-02-02 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −736 | $46.63 | $34K | 12,965 |
| 2026-02-02 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,844 | 3,025 | ||
| 2026-02-02 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −156 | 41,333 | ||
| 2026-02-02 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +15,000 | $10.42 | $156K | 15,000 |
| 2026-02-02 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −600 | $44.21 | $27K | 14,400 |
| 2026-02-02 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −8,364 | $45.89 | $384K | 6,036 |
Page 8 of 14 · 267 trades